Main Article Content
Aim: The purpose of this study was to compare between Clopidogrel and Ticagrelor on patients suffering from Chronic Obstructive Pulmonary Disease and Acute Coronary Syndrome:
Study design: PLATO trial based analysis
Place and duration: This study was conducted at Peoples University of Medical and Health Sciences for Women Shaheed Benazirabad Nawabshah, Pakistan from Jan2019 to Jan 2020.
Methodology: A total of 18,614 patients suffering from ACS randomly giving treatment with either clopidogrel or ticagrelor. In these patients, 1084 (5.7%) patient reported with a history of COPD. The primary endpoint at end of one year was seen in 18% of the patients suffering from COPD, and 10% for patients without COPD.
Results: In the case of primary endpoints in patients with COPD, the one-year event rate for patients who were given ticagrelor was 15% and 20% for those that were treated with clopidogrel. The occurrence of death for patients taking clopidogrel was 11.9% and it was 8.6% for the patients being treated with ticagrelor. Whereas Platelet Inhibition and Patient Outcomes defined that the major bleeding rates for one year was 15% for the patients being treated with ticagrelor and 17% for patients being treated with clopidogrel. Cases of dyspnea are more common in patients who took ticagrelor. Another important point to note is that there was no differential increase in the risk of getting as compared to patients that were not suffering from COPD (1).
Conclusions: After thoroughly analyzing the data, it can be seen that COPD patients experienced a higher rate of ischemic events. With the use of either Ticagrelor or clopidogrel to treat COPD patients, the overall risk of ischemic events (5.7%) are reduced. Also, the major bleeding events were not increased. After assessing the benefit risk profile, it can be said that using Ticagrelor to treat patients is better.